Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

China Investors Add to Argos Holdings in Latest $60 Million Funding

publication date: Mar 8, 2016
Two affiliated China investors, Tianyi Lummy International and China BioPharma Capital, participated in a $60 million financing of North Carolina's Argos Therapeutics. One year ago, the two China companies agreed to a $40 million investment in Argos that included Lummy Pharma's acquisition of China rights to Argos' immunotherapy cancer treatment, Arcelis™. Argos said the latest capital raise will fund the company for 15 months, long enough to complete a Phase III trial of Arcelis. More details....

Stock Symbol: (NSDQ: ARGS)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital